Helix Investment Research
Long only, special situations, contrarian, growth

Buy NuPathe: When An FDA Rejection Creates An Opportunity

When a development stage biotechnology company receives a complete response letter (CRL) from the FDA, its shares almost always fall sharply, and its viability is called into question. But no company's viability can be determined on the basis of simply receiving a complete response letter. What matters is what is contained within that letter. And the contents of NuPathe's (PATH) complete response letter suggest that as the company heads into its resubmission PDUFA date, there is a buying opportunity for risk tolerant investors. For the record, unless otherwise noted, financial statistics and management commentary used in this article will be sourced from one of 3 places: the company's Q3 2012 conference call, its latest investor presentation,...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details